Compare · NVO vs OCEA
NVO vs OCEA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Ocean Biomedical Inc. (OCEA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and OCEA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $196.77B.
- Over the past year, NVO is down 39.5% and OCEA is up 0.0% - OCEA leads by 39.5 points.
- NVO has hit the wire 11 times in the past 4 weeks while OCEA has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for OCEA).
- Company
- Novo Nordisk A/S
- Ocean Biomedical Inc.
- Price
- $44.05-3.39%
- $0.02-46.75%
- Market cap
- $196.77B
- -
- 1M return
- +4.41%
- +0.00%
- 1Y return
- -39.50%
- +0.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest OCEA
- SEC Form NT 10-Q filed by Ocean Biomedical Inc.
- SEC Form 25-NSE filed by Ocean Biomedical Inc.
- Ocean Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events
- Ocean Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Ocean Biomedical Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Ocean Biomedical Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- SEC Form 10-Q filed by Ocean Biomedical Inc.
- Amendment: SEC Form 10-K/A filed by Ocean Biomedical Inc.
- Ocean Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events, Financial Statements and Exhibits
- Ocean Biomedical Expands into Energy and Digital Asset Sectors to Accelerate Growth and Shareholder Value